Metacrine Completes Series B Financing to Advance Best-in-Class FXR Program into Clinical Development

SAN DIEGO, Dec. 7, 2017 -- (Healthcare Sales & Marketing Network) -- Metacrine, Inc., an innovative biotechnology company focused on drug development, today announced it has closed a $22M Series B financing led by new investor New Enterprise Associates (N... Biopharmaceuticals, Venture Capital, Personnel Metacrine, FXR agonist
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news